Startups
Enzymatic Peptide Cross-Linking Technology to Redefine Therapeutic Peptide Design: Sethera Therapeutics
Mentions in press and media 4
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Aug 3, 2026 | Sethera Therapeutics and Receptor.AI Form Integrated Discovery Alliance for AI-Guided Polymacrocyclic Peptide Medicines | Collaboration combines Sethera's proprietary enzymatic polymacrocyclization and trillion-scale encoded screening with Receptor.AI's physics-based modeling SALT LAKE CITY, UT, UNITED STATES, August 3, 2026 /EINPresswire.com/ -- SALT LAKE CIT... |
| Oct 30, 2025 | Sethera Therapeutics Co-Founders Named Founders of the Year by the University of Utah Innovation Awards | Dr. Vahe Bandarian (left) and Dr. Karsten Eastman (right), have been honored with the Founders of the Year Award at the University of Utah’s third annual Innovation Awards Dr. Karsten Eastman (left) and Dr. Vahe Bandarian (right) have been ... |
| Sep 25, 2025 | Sethera Therapeutics Appoints Jeffery W. Kelly and Alexander M. Klibanov to Scientific Advisory Board | SALT LAKE CITY, UT, UNITED STATES, September 25, 2025 /EINPresswire.com/ -- Sethera Therapeutics, a biotechnology company advancing next-generation polymacrocyclic peptide therapeutics, today announced the appointment of two globally recogn... |